Posting Date: July 12, 2021

Closing Date: July 22, 2021 11:30 a.m.

ET Reference Number: 21-045956

To: NCI Bid Board

From: Tanya Proctor
NCI CCR P-ARC
Tanya.proctor@nih.gov

Subject: NCI Bid Board Posting – USDA Approved Fetal Bovine Serum, Heat Inactivated Lot #216821

The Laboratory of Tumor Immunology and Biology (LTIB) functions as a multidisciplinary and interdisciplinary translational research programmatic effort with the goal of developing novel immunotherapies for cancer. The LTIB strategic plan focuses on the development of novel immunotherapeutics, not only as monotherapies, but more importantly, in combination with other immune-mediating modalities, and other conventional or experimental therapies, as part of an immuno-oncology programmatic effort. Within this effort are several research groups and a clinical trials group, and multiple collaborations with intramural and extramural scientific and clinical investigators, and with investigators in the private sector.

The National Cancer Institute plans to purchase USDA Approved Fetal Bovine Serum, Heat Inactivated Lot #216821 from Omega Scientific. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on July 22, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

The laboratory would like to purchase a large lot 75 bottles of a remaining lot that has been tested and used previously in the LTIB. These results have been exceptional, and this lot of sera will reduce the probability of introducing new variables in the experimental results. Changing the variables now would result in incorrect interpretation of the immune assays in progress. We want to keep the continuity of ongoing experiments.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request